- Home
- DCM vs INAB Comparison
DCM vs INAB Comparison
Compare DCM & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCM | INAB |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 11.8M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DCM | INAB |
|---|---|---|
| Price | $3.80 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | N/A | ★ 36.7K |
| Earning Date | 01-30-2018 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,847,163.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | N/A | $0.88 |
| 52 Week High | N/A | $2.73 |
Technical Indicators
Market Signals| Indicator | DCM | INAB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 35.57 |
| Support Level | N/A | $0.92 |
| Resistance Level | N/A | $1.22 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 20.33 |
Price Performance
Historical ComparisonAbout INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.